DREW J. WINSTON, M.D.; WILLIAM K. LAU, M.D.; ROBERT PETER GALE, M.D., Ph.D.; LOWELL S. YOUNG, M.D.
Intravenous trimethoprim-sulfamethoxazole therapy was evaluated in 11 consecutive patients with documented Pneumocystis carinii pneumonia and the results compared to those from previously published studies of trimethoprim-sulfamethoxazole therapy for P. carinii pneumonia. Although six patients needed mechanical ventilation, intravenous therapy was successful in seven of 11 patients (64%), and seven of nine patients (78%) receiving 4 or more days of intravenous trimethoprim-sulfamethoxazole therapy were cured. Side effects occurred in two patients (skin rash in one, nausea and vomiting in one). A review of 80 reported cases of confirmed P. carinii pneumonia initially treated with trimethoprim-sulfamethoxazole alone revealed response rates of 67.5% in all treated patients and 85.5% in patients treated for 9 or more days. The clinical response was similar in adults (63.2%) and children (68.9%). Side effects were noted in only 11 of 80 patients (13.8%). Compared to pentamidine, trimethoprim-sulfamethoxazole has a narrower toxic-therapeutic ratio and should be preferred treatment for P. carinii pneumonia in adults as well as children.
WINSTON DJ, LAU WK, GALE RP, YOUNG LS. Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis carinii Pneumonia. Ann Intern Med. ;92:762–769. doi: 10.7326/0003-4819-92-6-762
Download citation file:
Published: Ann Intern Med. 1980;92(6):762-769.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use